MT-1, also called Melanotan 1 or afamelanotide, is a melanocortin peptide related to skin pigmentation. The regulated prescription drug form, Scenesse, is FDA-approved only for adults with erythropoietic protoporphyria. Research-use MT-1 sold online is not the same as a prescribed medication and is not intended for self-use 1.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy MT-1 peptide legally?
You may see MT-1 peptide listed online, but that does not mean it is a legal patient medication. For patients, the key split is prescription afamelanotide, which is regulated for a rare disease, versus research-use Melanotan 1 products, which are not approved for human use.
The short answer for patients
Afamelanotide is a prescription drug in the United States under the brand name Scenesse. The FDA-approved indication is to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, or EPP 1.
That is very different from buying a vial labeled “Melanotan 1” or “MT-1” online. Those research-use products are not reviewed by FDA as patient drugs for safety, dosing, sterility, or effectiveness 2.
Why online research peptide listings are not the same as prescriptions
A prescription medication has a defined indication, manufacturing controls, labeling, adverse-event monitoring, and clinician oversight. Research-use-only peptides are marketed for laboratory work, not for human diagnosis, treatment, tanning, or wellness use 2.
This matters because melanocortin peptides can affect skin pigment, moles, nausea, appetite pathways, blood pressure symptoms, and sexual-function pathways depending on the receptor activity involved 3. The possible benefits and the risks need medical context, not a product listing.
What is MT-1 peptide used for?
MT-1, or Melanotan 1, is discussed in research as an analog of alpha-melanocyte-stimulating hormone, also called alpha-MSH. In regulated medicine, afamelanotide is used for one approved purpose: helping adults with EPP tolerate more light exposure before pain starts 1.
How MT-1 relates to alpha-MSH and melanocortin receptors
Alpha-MSH is a natural signaling peptide that binds melanocortin receptors. Afamelanotide is a synthetic analog that mainly acts through melanocortin-1 receptor, or MC1R, on melanocytes, the pigment-making cells in skin 3.
MC1R signaling can increase production of eumelanin, a darker form of melanin. That biology helps explain why the same pathway is studied for pigmentation and light sensitivity, but it does not make cosmetic tanning use medically approved or safe 3.
Why MC1R matters for pigmentation and light sensitivity
In EPP, light can trigger painful phototoxic reactions. Afamelanotide does not fix the genetic cause of EPP; it is approved to increase pain-free light exposure in adults with a history of these reactions 1.
In two phase 3 trials published in the New England Journal of Medicine, afamelanotide improved pain-free light exposure compared with placebo in patients with EPP, and nausea, headache, and implant-site reactions were among reported adverse events 4. Individual results vary.
Why tanning, cosmetic, or wellness uses are different from approved use
Using a melanocortin peptide for tanning or general wellness is not the same as treating EPP under specialist care. Cosmetic use can still change pigmentation and moles, and reported concerns with unregulated melanotan products include nausea, flushing, darkening of nevi, and quality problems with online products 5.
Is Melanotan 1 a prescription medication?
Afamelanotide is a prescription medication when used as Scenesse for EPP. Online “Melanotan 1” is often a research-use peptide, which is not the same thing as a clinician-prescribed medication.
Afamelanotide vs research-use Melanotan 1
Scenesse is supplied as an implant for subcutaneous administration by a trained professional, not as a self-injected tanning vial 1. The labeled implant contains afamelanotide and is used in a defined EPP care pathway.
Research-use MT-1 products may use overlapping names, such as Melanotan 1, NDP-MSH, or afamelanotide-like language. Naming overlap does not mean the product has FDA-reviewed manufacturing, dosing, safety, or outcomes data for patient use 2.
What prescription-only access means
Prescription-only access means a clinician must confirm the medical reason, review risks, and decide whether the medication fits the patient. For EPP, that often involves specialty evaluation, documentation of phototoxic symptoms, and monitoring for adverse effects 1.
This protects patients because melanocortin effects are not limited to skin color. Depending on the compound, this drug family can involve MC1R, MC3R, MC4R, and MC5R pathways, which can affect pigmentation, appetite, nausea, blood pressure symptoms, and sexual arousal biology 3.
How are MT-1, MT-2, and PT-141 different?
MT-1, MT-2, and PT-141 all sit near the melanocortin family, but they are not interchangeable. Their receptor activity, approved uses, safety concerns, and access pathways are different.
MT-1: more MC1R-focused melanocortin activity
MT-1, often used to mean Melanotan 1, is closest to the afamelanotide discussion. Afamelanotide’s regulated use focuses on MC1R-related pigmentation biology for EPP, with known risks including nausea, headache, skin hyperpigmentation, and implant-site reactions 1.
MT-2: broader receptor activity and no approved human product
Melanotan 2, or MT-2, is a different peptide with broader melanocortin receptor activity. Reviews and safety reports describe MT-2 as affecting receptors beyond MC1R, including pathways linked with appetite and sexual effects, and it has no FDA-approved human indication 3.
Case reports and pharmacovigilance concerns have linked unregulated melanotan products with changing moles, possible melanoma-related concerns, nausea, flushing, and other adverse events 5. These reports do not prove every case was caused by the peptide, but they are a clear reason not to self-dose.
PT-141: a distinct melanocortin peptide with different clinical context
Bremelanotide, also called PT-141, is distinct from MT-1 and MT-2. The FDA-approved bremelanotide product is indicated for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women, and its label includes warnings about blood pressure increases, nausea, and contraindication with uncontrolled hypertension or known cardiovascular disease 6.
At Chia, PT-141 nasal spray is the melanocortin peptide in our current public catalog. It is available only through clinician review when clinically appropriate; it is not MT-1, MT-2, afamelanotide, or Scenesse.
| Peptide | Also called | Main clinical context | FDA-approved human indication? | Key safety notes |
|---|---|---|---|---|
| MT-1 | Melanotan 1; often discussed near afamelanotide | Pigmentation biology; regulated afamelanotide implant for EPP | Afamelanotide implant is approved for adults with EPP | Nausea, headache, skin hyperpigmentation, implant-site reactions; needs specialist evaluation |
| MT-2 | Melanotan 2 | Research peptide; tanning and sexual effects are often marketed online | No FDA-approved human indication | Broader receptor activity; reports of nausea, flushing, mole changes, and unregulated-product risks |
| PT-141 | Bremelanotide | Sexual desire pathway; distinct from MT-1 and MT-2 | FDA-approved bremelanotide injection exists for a specific HSDD indication | Can raise blood pressure and cause nausea; not for people with uncontrolled hypertension or known cardiovascular disease |
What are the safety concerns with buying MT-1 online?
The biggest safety issue is that research-use-only MT-1 is not a patient medication. A vial sold online may not have FDA-reviewed sterility, identity, purity, storage, dosing, or human safety data.
Research-use-only products are not patient medications
FDA regulation separates drugs intended for human use from chemicals sold for research. A “not for human consumption” label is a major warning that the product is not being sold as a regulated prescription medication 2.
Purity, sterility, dosing, and contamination risks
With online research peptides, the buyer may not be able to verify the active ingredient, concentration, sterility, endotoxin testing, cold-chain handling, or whether the product matches the label. These quality gaps raise the risk of infection, dosing error, and unexpected reactions 7.
Why self-injection and self-dosing increase risk
Self-injection adds risks such as contamination, skin infection, needle injury, and dosing mistakes. With melanocortin peptides, self-dosing also skips screening for skin history, cardiovascular risk, medication interactions, pregnancy status, and the actual medical reason for use 5.
Skin changes, pigmentation effects, and the need for medical evaluation
Melanocortin peptides can darken skin and nevi. Because changing moles can also signal skin cancer, new or changing pigmented lesions should be evaluated by a qualified clinician rather than treated as a normal tanning effect 8.
3-min quiz
Have questions about melanocortin peptides?
Chia does not offer MT-1, Melanotan 1, afamelanotide, Scenesse, or MT-2. If your goals relate to sexual wellness, Chia offers PT-141 nasal spray through an online clinician review when clinically appropriate. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
How expensive is Melanotan or afamelanotide?
Melanotan pricing online can be misleading because a research vial is not the same as prescription afamelanotide care. Scenesse access usually runs through specialty diagnosis and treatment pathways, while online vial prices often leave out medical evaluation, safe administration, monitoring, and quality controls.
Why Scenesse pricing and access differ from research peptide listings
Scenesse is a regulated implant used for adults with EPP and administered by trained professionals under its prescribing information 1. The cost picture may include specialty visits, diagnosis, payer rules, monitoring, and site-of-care logistics.
Why online vial prices can be misleading
An online MT-1 vial price may look simple, but it is not a prescription-care price. It may not include clinician evaluation, sterile administration supplies, validated compounding or manufacturing controls, adverse-event follow-up, or confirmation that the product is appropriate for the patient 7.
Questions to ask a licensed clinician or specialty center
- What diagnosis is being evaluated, and does it have an approved treatment pathway?
- Is afamelanotide appropriate for this condition, or is the online product a research-use peptide?
- Who administers the medication, and how are side effects monitored?
- What skin checks or follow-up are needed before and after treatment?
- What costs may be billed through insurance, specialty pharmacy, or the treatment center?
Melanocortin peptides at Chia: what is and is not available
Chia does not offer MT-1, Melanotan 1, afamelanotide, Scenesse, or MT-2. We do offer PT-141 nasal spray, a distinct melanocortin peptide, through a licensed-provider review when clinically appropriate.
Chia does not offer MT-1, Melanotan 1, afamelanotide, Scenesse, or MT-2
Based on our current public treatment catalog, MT-1 and MT-2 are education-only topics at Chia. We do not present research-use melanotan products as patient medications, and we do not offer afamelanotide or Scenesse.
Chia offers PT-141 nasal spray through clinician review when clinically appropriate
Chia offers compounded PT-141 nasal spray, with plans currently starting at $159/month. PT-141 is distinct from MT-1 and MT-2, and a Chia prescription requires review by a licensed US provider.
Chia also offers the Spark protocol, which is PT-141 nasal spray, with plans currently starting at $159/month. The FDA-approved bremelanotide label includes important safety limits, including blood pressure effects and contraindications for uncontrolled hypertension or known cardiovascular disease 6.
| Chia option | Form | Current starting price | How access works |
|---|---|---|---|
| PT-141 | Nasal spray | From $159/mo | Online questionnaire, licensed US provider review, prescription only when clinically appropriate, 503A pharmacy fulfillment, home delivery |
| Spark protocol | PT-141 nasal spray | From $159/mo | Same clinician-reviewed pathway; prescription is not guaranteed |
How Chia treatment access works
At Chia, care starts with a 100% online health questionnaire. A licensed US provider reviews your information and prescribes only when clinically appropriate; you can start with the eligibility quiz, but a prescription is never guaranteed.
When prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door. Dosing is provider-guided, and patients can message the care team through the portal between visits.
What should you do if you are considering MT-1?
Start with the medical reason, not the peptide listing. MT-1 online may look easy to order, but the safer path is to ask what condition you are trying to address and whether a licensed, regulated pathway exists.
Start with the medical reason, not the product listing
If the concern is severe light sensitivity, painful sun reactions, or possible EPP, a clinician can evaluate symptoms and decide whether specialty testing or referral is needed. Afamelanotide’s approved use is narrow, and it is not a general tanning medication 1.
Avoid using research-only peptides for self-treatment
Do not treat a research-use label as a workaround for medical care. The main safety line is licensed versus unlicensed access: a licensed clinician and regulated pharmacy pathway gives you evaluation, documentation, quality controls, and follow-up that an online research vial does not 2.
Use a licensed medical pathway for prescription medications
For medications Chia offers, that means online evaluation by a licensed US provider, 503A pharmacy fulfillment when prescribed, and ongoing support. For MT-1, MT-2, afamelanotide, or Scenesse, Chia does not offer those products, so a specialty clinician is the right place to ask condition-specific questions.
3-min quiz
Explore clinician-reviewed PT-141 access
If your question is really about PT-141 rather than MT-1 or MT-2, Chia offers PT-141 nasal spray and the Spark protocol through licensed-provider review. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
FAQ
MT-1 usually refers to Melanotan 1, a synthetic alpha-MSH analog studied for melanocortin signaling and pigmentation biology. The regulated prescription drug in this pathway is afamelanotide, sold as Scenesse, which is FDA-approved for increasing pain-free light exposure in adults with erythropoietic protoporphyria.
The names overlap, but patients should be careful. Afamelanotide is the regulated prescription drug context. Online Melanotan 1 or MT-1 products are often research-use-only peptides and are not the same as a prescribed medication.
Yes. Scenesse is FDA-approved for adults with erythropoietic protoporphyria to increase pain-free light exposure. It is not approved as a tanning, cosmetic, or general wellness medication.
Research-use MT-1 products sold online are not approved patient medications and should not be used for self-treatment or tanning. A licensed clinician should evaluate any concern involving light sensitivity, pigmentation changes, or peptide use.
MT-2, or Melanotan 2, has no FDA-approved human indication. Products sold online are generally research-use products, not regulated prescription medications for patients.
No. Chia does not offer MT-1, Melanotan 1, afamelanotide, Scenesse, or MT-2 based on the current public treatment catalog.
Yes. Chia offers PT-141 nasal spray through an online licensed-provider review when clinically appropriate. PT-141 is distinct from MT-1 and MT-2, and a prescription is not guaranteed.
No. Compounded medications are not FDA-approved. At Chia, medications are compounded by state-licensed US 503A pharmacies when prescribed after clinician review.
References
- 1.U.S. Food and Drug Administration. Scenesse (afamelanotide) prescribing information. 2019.
- 2.U.S. Food and Drug Administration. Regulatory considerations for human cells, tissues, and cellular and tissue-based products and drugs; FDA regulation of medical products. 2024.
- 3.An overview of benefits and risks of chronic melanocortin-1 receptor agonist use. 2024.
- 4.Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine. 2015.
- 5.Medicines and Healthcare products Regulatory Agency. Melanotan: warning against use of unlicensed tanning injections. 2010.
- 6.U.S. Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. 2019.
- 7.U.S. Food and Drug Administration. BeSafeRx: Know your online pharmacy. 2024.
- 8.American Academy of Dermatology Association. What to look for: ABCDEs of melanoma. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
